Clinical Trials Logo

Neoplasms Malignant clinical trials

View clinical trials related to Neoplasms Malignant.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05650385 Not yet recruiting - Neoplasms Malignant Clinical Trials

A Study of B1962, a PD-L1/VEGF Bispecific Antibody Fusion Protein, for Advanced Solid Tumors

Start date: December 2022
Phase: Phase 1
Study type: Interventional

This study is to characterize the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of B1962, a PD-L1/VEGF bispecific antibody fusion protein, as a single agent in adult subjects with advanced solid tumor malignancies. The study consists of two parts: a once-weekly (QW) dosing phase and a biweekly (Q2W) dosing phase, which will explore the possibility of Q2W dosing of B1962 based on the PK data obtained in the QW phase. The study will determine the maximum tolerated dose (MTD), or recommended Phase 2 dose (RP2D) for B1962 as a single agent.

NCT ID: NCT03903848 Not yet recruiting - Neoplasms Malignant Clinical Trials

Cancer Survivors Acute Exercise Response 1

Start date: July 1, 2019
Phase: N/A
Study type: Interventional

The aims of this study examine the immune system, muscle metabolism, and autonomic nervous system response to an acute bout of exercise. Cancer survivors will participate in an acute bout of exercise. Blood samples will be collected before the exercise bout and at two time points after the exercise bout to assess the proposed variables.